Stocktoria
CRISPR Therapeutics AG CRSP
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2016-10-19
Chart by TradingView
1/9
Piotroski F — financial health
6.42
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Valuation · market cap as of 2026-06-29
Market cap$5.3B
P / B2.8×
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $3.5M | $37.3M | $371.2M | $1.2M | $915.0M |
| Operating income | -$664.6M | -$466.6M | -$222.5M | -$673.2M | $373.5M |
| Net income | -$581.6M | -$366.3M | -$153.6M | -$650.2M | $377.7M |
| Operating cash flow | -$345.0M | -$142.8M | -$260.4M | -$495.7M | $539.0M |
| Free cash flow | -$345.9M | -$144.7M | -$269.8M | -$532.9M | $457.3M |
| Total assets | $2.3B | $2.2B | $2.2B | $2.2B | $2.8B |
| Total liabilities | $343.4M | $310.0M | $346.8M | $367.6M | $352.4M |
| Shareholders' equity | $1.9B | $1.9B | $1.9B | $1.9B | $2.4B |
| Ratios | |||||
| Operating margin | -18933.6% | -1250.4% | -60.0% | -56190.4% | 40.8% |
| Net margin | -16569.8% | -981.5% | -41.4% | -54271.7% | 41.3% |
| FCF margin | -9855.5% | -387.7% | -72.7% | -44484.9% | 50.0% |
| Return on assets | -25.7% | -16.3% | -6.9% | -29.0% | 13.7% |
| Return on equity | -30.3% | -19.0% | -8.2% | -34.7% | 15.7% |
| Debt / equity | 0.00× | — | — | — | — |
| Current ratio | 13.32 | 22.07 | 17.54 | 15.30 | 20.17 |
| Revenue growth | -90.6% | -89.9% | 30885.5% | -99.9% | 127154.9% |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 6.42 (safe)
- Working capital / assets 0.811
- Retained earnings / assets -0.86
- EBIT / assets -0.293
- Equity / liabilities 5.596
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001674416 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.